CTXR
Citius Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.59
−2.38%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 7.1M | — | — | — | — |
| Cost of Revenue | 5.7M | 214.3K | 209.6K | — | — |
| Gross Profit | 1.4M | (214.3K) | (209.6K) | — | — |
| Operating Expenses | |||||
| R&D Expense | 5.9M | 9.2M | 11.9M | 14.8M | 17.7M |
| SG&A Expense | 43.3M | 18.5M | 18.2M | 21.9M | 15.7M |
| General & Admin Expense | 33.3M | 18.5M | 18.2M | 21.9M | 15.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 13.6M | 10.6M | 11.8M | — | — |
| Total Operating Expenses | 62.8M | 38.3M | 42.0M | 36.7M | 33.3M |
| Cost and Expenses | 68.5M | 38.5M | 42.0M | 36.7M | 33.3M |
| Operating Income (EBIT) | (61.4M) | (38.5M) | (42.0M) | (36.7M) | (33.3M) |
| Non-Operating | |||||
| Interest Income | 268.8K | 110.1K | 758.0K | 1.2M | 251.4K |
| Interest Expense | 695.3K | 267.8K | — | — | — |
| Net Interest Income | (426.5K) | (157.7K) | 758.0K | 1.2M | 251.4K |
| Other Non-Op Income/Expense | 3.4M | (157.7K) | 3.1M | 4.8M | 251.4K |
| Non-Operating Income (excl Interest) | (53.4K) | (110.1K) | (3.1M) | — | — |
| EBT (Pre-Tax Income) | (58.0M) | (38.7M) | (38.8M) | (32.0M) | (33.1M) |
| Income Tax Expense | 189.9K | 1.1M | 576.0K | 576.0K | 576.0K |
| Bottom Line | |||||
| Net Income | (46.3M) | (37.4M) | (39.1M) | (32.5M) | (33.6M) |
| Earnings from Cont. Ops | (58.2M) | (39.7M) | (39.4M) | (32.5M) | (33.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (46.3M) | (37.4M) | (40.2M) | (33.7M) | (33.6M) |
| Per Share | |||||
| Basic EPS | ($2.11) | ($3.38) | ($5.97) | ($5.57) | ($5.75) |
| Diluted EPS | ($2.11) | ($3.38) | ($5.97) | ($5.57) | ($5.75) |
| Revenue Per Share | $0.27 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 26.2M | 11.1M | 11.6M | 6.1M | 5.8M |
| Diluted Shares Outstanding | 26.2M | 11.1M | 11.6M | 6.1M | 5.8M |
| Profitability Metrics | |||||
| EBITDA | (57.2M) | (38.2M) | (38.6M) | (36.5M) | (33.1M) |
| D&A | 4.2M | 214.3K | 209.6K | 194.3K | 179.7K |
| EBIT | (61.3M) | (38.4M) | (38.8M) | (36.7M) | (33.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026